Drug Profile
Research programme: diabetes/obesity therapy - Xantos Biomedicine
Alternative Names: XAP A; XAP BLatest Information Update: 09 Feb 2011
Price :
$50
*
At a glance
- Originator Xantos Biomedicine
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 07 Mar 2005 The programme is available for licensing (http://www.xantos.de)
- 07 Mar 2005 Preclinical trials in Obesity in Germany (unspecified route)
- 07 Mar 2005 Preclinical trials in Type-2 diabetes mellitus in Germany (unspecified route)